Results from the treatment of refractory diabetic macular oedema with Bevacizumab in a clinical setting

Abstract

AbstractPurpose To evaluate the outcome of the treatment of patients with refractory diabetic macular oedema with intravitreal bevacizumab (Avastin).Methods Prospective data was entered into an in house database of all patients being treated for refractory diabetic macular oedema at the Ophthalmology Department, Central Middlesex Hospital, London, UK. All patients received bevacizumab on a pro re nata basis after an initial loading phase of three injections. Best corrected visual acuity (BCVA) on the logMAR chart and the central retinal thickness (CRT) on the optical coherence tomography (OCT) scan were recorded at each visit. OCT was performed with the Spectralis OCT device (Heidelberg Engineering, Heidelberg, Germany) using the standard protocol of the clinic. Statistical analysis involved the Wilcoxon signed rank test and Spearman correlation test.Results 64 eyes of 48 patients were included in this study. The mean age was 68 years (range 45 ‐ 87). Patients received a mean of 3 bevacizumab (range 1‐10) injections. The follow‐up time was up to 15 months. The mean logMAR BCVA at baseline for Avastin was 0.74. At 2, 3, 7, and 11 months the mean BCVA was 0.77, 0.75, 0.67, and 0.69 respectively (p=0.01, 0.006, 0.02 and 0.05). There was no significant difference between baseline and any period thereafter during follow‐up to 15 months. Mean CRT at baseline was 527μm. The mean CRT at months 1‐4 were 456, 491, 490 and 480μm respectively and were significantly different for baseline, (p=0.001, 0.01, 0.03 and 0.04). CRT for months 5 to 15 were not significantly different from baseline.Conclusion The treatment of refractory diabetic macular oedema with intravitreal bevacizumab made little difference to improving the BCVA and CRT of the patients.